問卷

TPIDB > Search Result

Search Result

篩選

List

97Cases

2023-11-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2024-01-10 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-11-01 - 2030-12-31

Phase II

Not yet recruiting
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  • Condition/Disease

    Chronic obstructive pulmonary disease

  • Test Drug

    prefilled syringe

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2022-01-01 - 2024-04-23

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-10-01 - 2024-12-31

Phase III

Completed
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
  • Condition/Disease

    Relapsing Multiple Sclerosis

  • Test Drug

    SAR442168 60mg or Teriflunomide 14mg or placebo

Participate Sites
6Sites

Recruiting6Sites

2025-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-04-01 - 2028-12-31

Phase II

Active
An Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis
  • Condition/Disease

    moderate to severe atopic dermatitis

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites

2023-12-01 - 2027-12-31

Phase I

Completed
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01
  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MYTX-011

Participate Sites
6Sites

Recruiting6Sites

2023-03-01 - 2026-10-30

Phase I

Active
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
  • Condition/Disease

    HER2 Mutant Non-small Cell Lung Cancer

  • Test Drug

    膠囊劑 注射劑 注射劑

Participate Sites
5Sites

Recruiting5Sites